2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Treatment Considerations, Supportive Care, Biological Therapies, Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Quality Improvement, Systems-Based Hematology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Genetic Disorders, Immunology, Autoimmune Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Pediatric
PAPER

3079 From early prediction to dynamic surveillance: Clinically accessible models for transplant-associated thrombotic microangiopathy in aplastic anemia post allogeneic hematopoietic stem cell transplantation

Tianye Zhou, Yun Zhang II, MMed2, Yingying Shen3, Yuhui Pang4, Yi Chen5, Xiaowei Chen6, Wenbin Liu7, Qinghong Yu Jr, Practicing Certificate for Licensed Physician8, Yuanbin Wu9, Xinru Jia10, Xiawan Yang11, Jing-Yi Wang, PhD12, Yang Xu, MD13, Jianying Li14, Yi Ying15, Tonglin Hu16, Jianping Shen17, Baodong Ye, MD, PhD18, Weijie Cao19, Dijiong Wu, MD,PhD20
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
4 Shijiazhuang Pingan Hospital, Shijiazhuang, Hebei, China
5 The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
6 Guangzhou First People's Hospital, Guangzhou, Guangdong, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
8 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
9 Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China
10 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
11 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
12 Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China
13 The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
14 Shijiazhuang Pingan Hospital, Shijiazhuang, Hebei, China
15 Guangzhou First People's Hospital, Guangzhou, Guangdong, China
16 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
17 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
18 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
19 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
20 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China

Introductions: Transplantation-associated thrombotic microangiopathy (TA-TMA) is a severe and potentially fatal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Patients with aplastic anemia (AA) are particularly susceptibility to TA-TMA because of cumulative endothelial injury from repeated transfusions, iron overload, prolonged immunosuppressive therapy, and recurrent infections before HSCT, and continued exposure to calcineurin inhibitors after transplantation. Under the "multiple-hit" hypothesis, these sequential stressors may collectively promote endothelial dysfunction and subsequent TA-TMA. Despite this disease-specific risk profile, predictive strategies for TA-TMA remain limited, particularly in AA. Previous studies have largely focused on specialized biomarkers about endothelial injury or complement activation, whose clinical implementation is constrained by the requirement for specialized laboratory assays and limited routine availability. Given the relatively high incidence of AA in Asia and the growing use of allo-HSCT as a curative treatment, large AA transplant cohorts now provide an opportunity to develop disease-specific prediction models. Therefore, an AA-specific prediction framework based on routinely available variables was developed and externally validated for early risk stratification and dynamic surveillance of TA-TMA. This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang Chinese Medical University (2025-KLS-666-01).

Methods: Consecutive patients with AA undergoing allo-HSCT at Zhejiang Provincial Hospital of Chinese Medicine between May 2019 and May 2026 were retrospectively reviewed. TA-TMA was diagnosed according to the modified Jodele criteria. Eligible patients were divided into derivation (May 2019 to May 2025) and temporal validation (May 2025 to May 2026) cohorts. Candidate predictors were selected by univariable analysis, least absolute shrinkage and selection operator (LASSO) regression, and multivariable logistic regression. A dual-window prediction framework was developed and evaluated using receiver operating characteristic (ROC) curves, calibration, and decision curve analysis (DCA). Geographic generalizability was assessed in an independent multicenter cohort.

Results: Among 247 consecutive patients with AA undergoing allo-HSCT, 156 met the criteria, including 122 in the derivation cohort and 34 in the temporal validation cohort. An independent multicenter cohort from 7 Chinese centers of 103 patients served as the geographic external validation cohort. The 1-year cumulative incidence of TA-TMA was 10.14% (95% CI, 4.7%–15.6%), with a median onset of 74.5 days (IQR, 61.5–121) after transplantation. Patients who developed TA-TMA had significantly higher all-cause mortality than those without TA-TMA (45.5% vs. 19.0%). Two complementary prediction models covering distinct post-transplant windows were established: a creatinine-based model enabled early risk prediction, incorporating infused CD34? cell count (OR, 0.794; 95% CI, 0.634–0.993), ΔCREA30 (OR, 1.031; 95% CI, 1.010–1.052), and intestinal acute graft-versus-host disease (aGVHD) (OR, 5.160; 95% CI, 1.635–16.282), whereas a LDH-based model identified patients at imminent risk of TA-TMA, based on infused CD34? cell count (OR, 0.621; 95% CI, 0.409–0.944), ΔLDH (OR, 1.017; 95% CI, 1.008–1.025), and intestinal aGVHD (OR, 7.684; 95% CI, 1.395–42.336). Both models showed excellent discrimination, with AUCs of 0.856 (95% CI, 0.754–0.957) and 0.956 (95% CI, 0.904–1.000), respectively, and maintained robust discrimination, calibration, and clinical utility in temporal and geographic external validation cohorts. Risk stratification identified low-, intermediate-, and high-risk groups with significantly different cumulative incidences of TA-TMA (both log-rank P<0.001). Trajectory analysis revealed divergent outcomes: 79.1% of patients with persistently low-risk or de-escalating trajectories remained free of TA-TMA, while 84.9% of those with persistently high-risk or escalating trajectories developed TA-TMA.

Conclusions: A practical dual-window prediction framework was developed and externally validated for TA-TMA in patients with AA undergoing allo-HSCT. Using routinely available variables, the framework enables both early risk stratification and dynamic surveillance of imminent TA-TMA, supporting individualized monitoring and timely intervention in clinical practice.

Tianye Zhou: No relevant conflicts of interest to declare.